Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
2024年10月8日 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), meeting the primary end point of the phase 3 KEYNOTE-689 study (NCT03765918). 1 “These results are substantial, as KEYNOTE-689 marks the first positive trial in 2 decades for patients with resected, locally advanced head ...
Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
6-Year Data Sustain Adjuvant Olaparib Benefit in BRCA1/2+, HER2 …
2024年12月11日 · Six-year results continued to show the clinically meaningful efficacy of adjuvant olaparib vs placebo in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, according to findings from the third pre-specified analysis of the phase 3 OlympiA trial (NCT02032823). 1. The analysis occurred at a median follow-up of 6.1 years (max, 9.6 years) and 2.6 years since the ...
Palbociclib Combo Shows Benefit to PFS in HR+, HER2+ Breast …
2024年12月12日 · A statistically significant and clinically meaningful median progression-free survival (PFS) improvement was demonstrated with palbociclib (Ibrance) plus standard-of-care therapy in patients with hormone receptor–positive, HER2-positive metastatic breast cancer as first-line maintenance therapy. 1 “Our results really reinforce the strong scientific rationale for overcoming resistance to ...
TMB and Gene Profiles Confirm Prognostic Value in TNBC
2024年12月11日 · Various biomarkers, including T-cell inflamed 18-gene expression profile, were positively prognostic for improved pathologic complete response (pCR) and event-free survival (EFS), with or without the addition of pembrolizumab (Keytruda; P ≤.001), according to findings from a prespecified, exploratory analysis of the KEYNOTE-522 study (NCT03036488) in high-risk, early triple-negative breast ...
GLP-1 Agonists Poised to Impact Breast Cancer Care
2024年9月25日 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing general weight loss. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, multiple presentations focused on the weight loss aspect of GLP-1 agonists for patients with breast cancer.
FDA Reviews NDA for Dordaviprone in H3K27M-Mutant Diffuse …
2025年1月3日 · The FDA is reviewing a new drug application (NDA) for dordaviprone (ONC201), a potential treatment for patients with recurrent H3K27M-mutant diffuse glioma.; Clinical data show a 20% overall response rate (ORR) and a median response duration (DOR) of 11.2 months, with manageable safety profiles observed across multiple trials and …
Navtemadlin Monotherapy Shows Improvements in Hallmarks of …
2024年12月8日 · Navtemadlin (KRT-232), a novel p53 potentiating anticancer agent best-in-class MDM2 inhibitor, reduced biomarkers of disease severity in patients with relapsed or refractory (R/R) myelofibrosis (MF), suggesting the agent may …
Perioperative Atezolizumab Falls Short in TNBC
2024年12月13日 · Adding atezolizumab (Tecentriq) to neoadjuvant chemotherapy followed by adjuvant atezolizumab did not significantly improve event-free survival (EFS) in patients with triple-negative breast cancer (TNBC), missing the primary end point of the phase 3 NSABP B-59/GBG-96-GeparDouze trial (NCT03281954). 1 Results presented at the 2024 San Antonio Breast Cancer Symposium showed that at a median ...
Tamoxifen Cuts 15-Year Recurrence in DCIS Without Radiation …
2024年12月13日 · Findings from an ancillary analysis of the phase 3 NRG/RTOG 9804 (NCT00003857) and ECOG-ACRIN E5194 (NCT00002934) trials, revealed that tamoxifen (Soltamox) significantly reduced 15-year ipsilateral breast recurrence (IBR) in patients with “good risk” ductal carcinoma in situ (DCIS) who were treated without radiation therapy.